ABBV AbbVie Inc

Q3 2025 10-Q

Filed: Nov 4, 2025Period ending Sep 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

AbbVie Inc (ABBV) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Revenue $15.8B Q3 2025, up 9.1% vs $14.5B Q3 2024; Nine months $44.5B, up 8.0% vs $41.2B prior year
• Gross margin approx. 66.4% Q3 2025 vs ~70.9% Q3 2024 (calc. from $10.47B/$15.78B vs $10.25B/$14.46B), decline due to $847M intangible impairments

+3 more insights

Risk Factors

• Section 'risk_factors' was empty or not found.

Quarterly Financial Summary
XBRL

Revenue

$15.8B

▲ +9.1% YoY▲ +2.3% QoQ

Net Income

$186M

▼ -88.1% YoY▼ -80.2% QoQ

Operating Margin

12.1%

▼ -1442bp YoY▼ -1966bp QoQ

Net Margin

1.2%

▼ -962bp YoY▼ -490bp QoQ

ROE

-7.0%

Total Assets

$133.9B

EPS (Diluted)

$0.10

▼ -88.6% YoY▼ -80.8% QoQ

Operating Cash Flow

$7.0B

▲ +29.0% YoY▲ +36.3% QoQ

Source: XBRL data from AbbVie Inc Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on AbbVie Inc

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.